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Sensitive quantitation of prions in biological samples is an extremely important and challeng-
ing analytical problem. Prions are the cause of several fatal neurodegenerative diseases known
as transmissible spongiform encephalopathies (TSEs). At this time, there are no methods to
diagnose TSEs in live animals or to assure a prion-free blood supply for humans. Prions have
been shown to be present in blood by transfusion experiments, but based on the amount of
infectivity found in these types of experiments, the amount of misfolded prion protein in blood
is estimated to be only 30 to 625 amol/mL. More sensitive detection of prions in brain would
allow earlier detection of disease and assure a safer food supply. We studied quantitation of
the prion protein by use of nanoscale liquid chromatography coupled to a tandem mass
spectrometer using the multiple reaction monitoring mode of operation. We developed a
method based on the detection of VVEQMCTTQYQK obtained by reduction, alkylation, and
digestion with trypsin of the prion protein. Detection of VVEQMCTTQYQK was more
sensitive than for the derivative with phenylisothiocyanate (PITC) because of decreased
ionization efficiency of the PITC-derivatized peptides. The VVEQMCTTQYQK method has a
LOD of 20 to 30 amol for pure standards. Proof of principle is demonstrated by quantitation
of the amount of PrP 27–30 in the brains of terminally ill Syrian hamsters. (J Am Soc Mass
Spectrom 2007, 18, 1070–1079) © 2007 American Society for Mass SpectrometryPrions are defined as infectious proteins [1], andhave been shown to maintain epigenetic states ineukaryotes. In mammals, a prion (PrPSc) is able to
facilitate the conversion of the host’s normal cellular
protein (PrPC) into PrPSc and thereby propagate an
infection. PrPSc is believed to be the cause of a group of
fatal neurodegenerative diseases called transmissible
spongiform encephalopathies (TSEs), known to affect
humans and a variety of other animals [2–5]. Detailed
studies show that the normal cellular isoform (PrPC)
and the infectious isoform (PrPSc) have identical amino
acid sequences and covalent post-translational modifi-
cations and, thus, the difference between PrPC and
PrPSc is believed to be exclusively conformational
[6 –10].
PrPC and PrPSc have distinct physico-chemical prop-
erties. For example, PrPC is rapidly degraded by pro-
teinase K (PK), whereas PrPSc is much more resistant to
PK degradation. The most studied PrPSc strain is the
263K strain propagated in hamsters. PK digestion of the
263K strain of PrPSc cleaves the amino terminal domain
to give an infectious core consisting primarily of 142
amino acids with an amino terminal Gly90 that isAddress reprint requests to Dr. Bruce Onisko, USDA/ARS/WRRC, 800
Buchanan St., Albany, CA 94710, USA. E-mail: bonisko@pw.usda.gov
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doi:10.1016/j.jasms.2007.03.009referred to as PrP 27–30 [2]. If the PK digestion of PrP Sc
is done in the presence of detergents, rod-shaped par-
ticles are obtained, composed of monomers of PrP
27–30. By use of chemical cross-linking and mass spec-
trometry, the amino terminal Gly90 residues of adjacent
monomers in PrP 27–30 rods have been shown to be
located within 11 Å of each other [11].
Sensitive prion detection is of importance, not only
for research purposes, but also to solve a variety of
problems such as the detection of preclinical TSE infec-
tions in humans and in animals (e.g., bovines, ovines,
cervids), for the assurance of a safe blood supply, and
for the early detection of prions in livestock. Prions are
present in the blood of infected animals, since the
disease has been shown to be transmitted by transfu-
sion [12]. However because of the high specific infec-
tivity of purified prion preparations (as high as 1011
infectious units (IU) per milligram of protein purified
from Syrian hamsters inoculated with strain 263K) [13],
and the fact that in rodent models of TSE, blood
contains 5 to 10 IU/mL in preclinical animals and a
maximum of about 100 IU/mL at the time of disease
onset, it has been estimated that blood contains about
0.05 to 1.0 pg (30 – 625 amol) of PrPSc per mL [14].
The incubation-time bioassay in hamster (or trans-
genic mice) is capable of detecting prions, but since
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number of animals, it is not practical for routine testing
[15]. Analytical methods have been developed for the
detection of PrPSc. They fall into three categories: West-
ern blots, enzyme-linked immunosorbent assays
(ELISAs), and the conformation dependent immunoas-
say (CDI). The most widely used test is the Western
blot, which is reported to detect between 10 to 20 pmol
of PrPSc [16 –18]. ELISA methodology is more sensitive,
and can detect 2 pmol of PrPSc [19 –21]. The CDI
immunoassay is the most sensitive method reported,
capable of detection of 0.1 pmol of PrPSc in brain
homogenate (2 ng of PrP of MW 16,241) [22]. Methods
to amplify prion titer before detection using either cell
culture [23] or cell-free conversion assays [24, 25] show
considerable promise. Despite the advancements made
in analytical methodology for prion analysis, appar-
ently the detection limit needs to be improved by about
three orders of magnitude to allow detection of prions
in blood (vide supra, 30 amol/mL in blood versus 0.1
pmol detection by the best antibody methods).
Recently, tandem mass spectrometric methods using
nanoscale chromatographic methods have demon-
strated selective detection of proteins in biological ma-
trices in sub-femtomole amounts [26, 27]. Furthermore,
it has been suggested that the sensitivity of MS/MS
detection of peptides may be improved through the use
of phenylisothiocyanate (PITC) derivatives, since the
MS/MS fragmentation of PITC derivatives gives con-
siderably simplified spectra and thereby may enhance
product ion yields [28, 29]. Whereas tandem mass
spectrometric methods have been used extensively in
the structural characterization of the prion protein
[6 –10], we are unaware of their use for prion quantita-
tion. We report the results of application of tandem
mass spectrometric methods to the problem of detection
of the prion protein, and to examine the effect of PITC
derivatization on MS/MS sensitivity.
Experimental
Chemicals
Trypsin for in-gel digestion (porcine, sequencing grade,
modified) was purchased from Princeton Separations,
Adelphia, NJ. Bovine trypsin used for solution diges-
tions was from Sigma (St. Louis, MO). Recombinant
Syrian hamster PrP (rPrP) comprising amino acids
90–231 was obtained from InPro Biotechnology (South
San Francisco, CA). The peptide VVEQMCTTQYQK,
containing an iodoacetamide-derivatized cysteine, was
synthesized by Anaspec (San Jose, CA). The structure of
this synthetic peptide was confirmed by mass spec-
trometry; its purity was greater than 90% as shown by
LC-UV, and the amount of peptide was quantitated by
amino acid analysis. HPLC grade water was purchased
from Burdick and Jackson (Muskegon, MI). Acetoni-
trile, HPLC grade, was from Fisher Scientific (Fairlawn,NJ). All other reagents were from Sigma-Aldrich (St.
Louis, MO).
Reduction, Alkylation, and Tryptic Cleavage
of Recombinant Syrian Hamster Prion Protein
(90–231)
Recombinant PrP containing residues 90–231 (6 nmol)
was dissolved in 20 L of 8 M guanidinium hydrochlo-
ride. The mixture was sonicated for 5 min and diluted
with 20 L of 1M TRIS (pH 8.0). To this solution was
added 5 L (1 mol) of a 200 mM solution of DTT in 1M
TRIS (pH 8.0). The reaction mixture was kept at 35 °C
for 60 to 90 min. After the reaction cooled to room
temperature, 20 L (4 mol) of a 200 mM solution of
iodoacetamide in 1M TRIS (pH 8.0) was added. The
reaction was kept at room temperature in the dark for
60 to 90 min. The excess iodoacetamide was quenched
by addition of an additional 25 L of the DTT solution.
The quenched solution was acidified with formic acid to
pH 1.5 to 2 (25 L). The reaction mixture containing the
derivatized protein was purified by HPLC using an
Alltech Altima C18 column (150 mm  2.1 mm i.d., 5
m particle diameter) using a flow rate of 0.25 mL/min
and a gradient of 20/80 to 60/40 (vol/vol) of A/B,
where solvent A was 0.1% aqueous TFA and solvent B
was acetonitrile/isopropanol/TFA ( 50/50/0.1). One
major chromatographic peak was observed (monitoring
the UV response at 210 nm) and was collected. The
identity and purity of the product was confirmed by
LC/ESI/MS. Solvents were removed with a stream of
nitrogen. The residue was dissolved in 400 L water
and the pH adjusted to 8.5 by addition of 1M NH4OH
(15 L). Bovine trypsin (3.3 g in 33 L water) was
added, and the reaction mixture was kept at 37 °C
overnight. The digestion was then stopped by addition
of formic acid (2 L) to give a pH of 2.3.
Derivatization of the rPrP Tryptic Digest
with PITC and Edman Cleavage
To 0.5 nmol of the tryptic digest was added 400 L of a
freshly prepared 5% solution of phenylisothiocyanate
(PITC) in ethanol/pyridine/water (1:1:1). The reaction
mixture was kept at 45 °C for 35 min, cooled to RT and
then extracted three times with 1 mL portions of 2:1
heptane/ethyl acetate; organic extracts were discarded.
A sample containing about 300 pmol of the PITC-
derivatized digest was taken to dryness with a stream
of nitrogen. The residue was redissolved in 5 L of TFA,
heated to 40 °C for 10 min, then cooled to RT and
diluted with 100 L of water.
Qualitative Mass Spectrometry: Nanospray
LC/MS/MS
NanoLC/ESI/MS/MS was done with an Applied Bio-
systems (ABI/MDS SCIEX, Toronto, Canada) model
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(Odense, Denmark) nanoelectrospray source. PrP digest
samples (20 L containing about 1 pmol) were loaded
automatically onto a C-18 trap cartridge and chromato-
graphed on a reversed-phase column (Vydac 238
EV5.07515, 75  150 mm; Hesperia, CA) fitted at the
effluent end with a coated spray tip (FS360-50-5-CE,
New Objective Inc., Woburn, MA). A nanoflow LC
system (Dionex, Sunnyvale, CA) with autosampler,
column switching device, loading pump, and nanoflow
solvent delivery system was used. Elution solvents
were: A (0.5% acetic acid in water) and B (80% acetoni-
trile, 0.5% acetic acid). Samples were eluted at 250
nL/min with the following binary gradient profile: 2%
B at 0 min to 80% B in a 15 min linear gradient; held at
80% B for 5 min then back to 2% B for 10 min. The QStar
Pulsar was externally calibrated daily and operated
above a resolution of 8000. The acquisition cycle time of
6s consisted of a single 1 s MS “survey” scan followed
by a 5 s MS/MS scan. Ions between m/z 400 to 1000 of
charge states between 2 to 5 having intensities
greater than 40 counts in the survey scan were selected
for fragmentation. The dynamic exclusion window was
set to always exclude previously fragmented masses.
Collision energy optimized for charge state andm/zwas
automatically selected by the Analyst QS software after
adjusting parameters to obtain satisfactory fragmenta-
tion of human [Glu1]-fibrinopeptide B (2), and human
adrenocorticotropic hormone (3 and 4). Nitrogen
was used for the collision gas and the pressure in the
collision cell ranged from 3  106 to 6  106 torr.
Quantitative Mass Spectrometry: Nanospray
LC/MS/MS
NanoLC/ESI/MS/MS was done with an Applied Bio-
systems (ABI/MDS SCIEX, Toronto, Canada) model
4000 Q-Trap instrument equipped with a nanoelectros-
pray source. Peptide samples (1 L containing 1 fmol of
human [Val5]-angiotensin II) were loaded automatically
onto a C-18 trap cartridge and chromatographed on a
reversed-phase column (Vydac 238EV5.07515, 75 x 150
mm; Hesperia, CA). A noncoated spray tip (FS360-20-
10-N-20-C12, New Objective Inc., Woburn, MA) was
used with the Applied Biosystem source, model Micro-
ionspray. An LC Packings nanoflow LC system (Di-
onex, Sunnyvale, CA) with autosampler, column
switching device, loading pump, and nanoflow solvent
delivery system was used. Elution solvents and gradi-
ent profile were the same as described above.
The instrument response was optimized by loop
injection of 20 L of a PrP digest at 1 pmol/L of
50/49.5/0.5 (acetonitrile/water/acetic acid) onto a re-
versed-phase column (Vydac 238EV5.07515, 75 x 150
mm; Hesperia, CA) using isocratic elution of 50/49.5/
0.5 (acetonitrile/water/acetic acid) at 250 to 300 nL/
min. This method gave stable analyte signals for more
than an hour per injection for tuning. Source parame-ters (electrospray voltage, curtain gas and nebulizing
gas settings, ion source heater temperature, decluster-
ing potential, and nanospray tip positioning relative to
the front plate orifice) were adjusted to obtain maxi-
mum analyte signal intensity in Q1MS scan mode while
maintaining stable (5%) electrospray intensity. Frag-
mentation to obtain specified product ions was opti-
mized by adjusting the Q2 offset voltage (“collision
energy”).
Syrian Hamster PrP 27–30
A crude preparation of PrP 27–30 was obtained from
brains of terminally ill Syrian hamsters inoculated in-
tracranially with the 263K strain of scrapie using mod-
ification of a method previously described [30]. Briefly,
pellet P145a (as described by Diringer et al. [30]) was
obtained, the next two detergent extraction steps were
not performed, and pellet P145a was treated with
benzonase and proteinase K as done with pellet P145c.
The final pellet containing PrP 27–30 was denatured by
addition of 6 M guanidinium hydrochloride, and pro-
tein was precipitated by centrifugation at 14,000 rpm for
20 min with an Eppendorf model 5417R centrifuge
(Hamburg, Germany) after addition of five volumes of
methanol at 0 °C.
Electrophoretic Purification and In-Gel Proteolytic
Digestion of PrP 27–30
The PrP 27–30 pellet was dissolved with reducing
Laemmli sample buffer, boiled for 10 min and subjected
to SDS-PAGE [31] using 4% to 12% NuPAGE gels
(Invitrogen, Carlsbad, CA). The gel was stained with
Coomassie blue, and the major protein bands were
excised. In-gel digestion was done with a DigestPro
(INTAVIS Bioanalytical Instruments AG, Bergisch
Gladbach, Germany). Following washing, reduction
with DTT, alkylation with iodoacetamide, and tryptic
digestion, the peptides were eluted with 40 ul of 10%
formic acid containing 0.1% trifluoroacetic acid.
Results and Discussion
Recombinant PrP (Syrian hamster, amino acid residues
90–231) was reduced with dithiothreitol, alkylated with
iodoacetamide, purified by HPLC, then analyzed by
nanoLC-ESI-TOF-MS (see Figure 1) to confirm identity of
the product. Data in Figure 1 show the presence of one
protein product present in charge states ranging from13
to 22. The m/z data shown was transformed using the
Bayesian Protein Reconstruct tool in the BioAnalyst ver.
1.1 software (Applied Biosystems, Foster City, CA), which
resulted in a measured average molecular weight of
16,357 Da (theoretical average MW of 16,357.1 for
C702H1073N211O221S11). The reduced and alkylated protein
was then digested with trypsin. The tryptic digest, both
before and after reaction with phenylisothiocyanate
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quadrupole time-of-flight (Q-TOF) mass spectrometer.
The four tryptic peptides that gave the most abundant
signal, listed in decreasing abundance, were: GENFTET-
DIK, ESQAYYDGR, PMMHFGNDWEDR, and VVEQM-
CTTQYQK. After reaction with PITC, the four derivatized
peptides that gave the most abundant signal, also listed in
decreasing abundance, were GENFTETDIK, QHTVTTTTK,
VVEQMCTTQYQK, and ESQAYYDGR. Proposed struc-
tures were confirmed by MS/MS analysis; see Figure 2
and Figure 3 for MS/MS of GENFTETDIK with and
without PITC derivatization. Underivatized GENFTET-
DIK gave a complex (information-rich) spectrum showing
excellent coverage of y ions and good coverage of b ions
(see Figure 3). PITC-derivatized GENFTETDIK gave a
very simple (information-poor) spectrum (see Figure 2)
containing primarily the products of gas-phase Edman
degradation (b1 and yn-1), as observed by others with
different PITC-derivatized peptides [28, 29]. The dramat-
ically simplified MS/MS spectrum of the PITC derivative
suggests that multiple reaction monitoring (MRM) analy-
sis of the PITC derivative using either b1 or yn-1 as the
selected product ion may give superior MRM response
Figure 1. NanoLC/ESI/TOF/MS analysis of
m/z.than the underivatized peptide.Experiments were done to determine which frag-
ment ion would give the best response for MRM
analysis for GENFTETDIK, VVEQMCTTQYQK, and
ESQAYYDGR before and after derivatization with
PITC. For each peptide, digest samples were directly
infused, ionized by nanoESI, and product ion scans
were obtained at collision energies ranging from 10 to
110 V. Three product ions were selected for each
peptide: the most abundant immonium ion (or frag-
ment thereof), the most abundant b (or a) ion, and the
most abundant y (or x ion). Next, instrumental param-
eters for each transition were optimized. Relative re-
sponses for these 18 optimized transitions were ob-
tained by nanoLC/MS/MS of injections of either the
underivatized or the derivatized tryptic digest with the
mass spectrometer operating in MRM mode. For all
three underivatized peptides (Table 1), monitoring the
product ion of m/z 84, which corresponds to the immo-
nium ion of lysine or glutamine (after loss of NH3), gave
the best detector response. For all three PITC-derivat-
ized peptides (Table 2), MRM using b1 as the product
ion gave the best response.
Direct comparison of the optimized nanoLC-MRM
ed and alkylated rPrP (90–231). The x axis isreducresponses of the three tryptic peptides of interest with
1074 ONISKO ET AL. J Am Soc Mass Spectrom 2007, 18, 1070–1079and without PITC derivatization was done with use of
human [Val5]-angiotensin II (1 fmol/injection) as an
internal standard added to each digest. Samples were
analyzed by nanoLC/MS/MS, and the MRM responses
for the peptides were measured relative to the MRM
response of the internal standard, and the MRM re-
sponse of each underivatized peptide relative to the
MRM response of the same peptide, after derivatization
was calculated. PITC derivatization gave a diminished
MRM response for all three peptides. The largest de-
crease, about 6-fold, was observed for GENFTETDIK.
The MRM response for ESQAYYDGR was 2.5-fold
greater than for PITC- ESQAYYDGR, and the MRM
response for VVEQMCTTQYQK was 1.3-fold greater
than for PITC- VVEQMCTTQYQK.
The decreased MRM responses seen for PITC-deri-
vatized peptides could be the result of chemical insta-
bility of the PITC derivatives, decreased ionization
efficiency, or decreased MRM efficiency. Potential
chemical instability of the PITC derivatives was of
concern, since our chromatographic solvents contained
Figure 2. Collision Activated Decomposition (C
collision energy of 22 V.dilute acid, and PITC derivatives are known to degradein acid. To test this possibility, the PITC-derivatized
rPrP digest was acidified and heated to release the
amino-terminal derivative. This sample was analyzed
by nanoLC/ESI/TOF/MS, which confirmed that the
desired cleavages had occurred. Furthermore, no PITC-
derivatized peptides remained, indicative of complete
reaction. ENFTETDIK is the expected degradation
product of PITC-GENFTETDIK. An MRM quantitation
method for ENFTETDIK was developed on the Q-Trap
model 4000 using a precursor ion ofm/z 547.7, a product
ion of m/z 706.4 and a collision energy of 28 V. Using
this method, and assuming a quantitative yield of
ENFTETDIK from PITC-GENFTETDIK, the amount of
ENFTETDIK in the PITC-derivatized rPrP digest was
determined. For injections of 1.2, 30, and 150 fmol of the
PITC-derivatized rPrP digest, ENFTETDIK, as a per-
centage of the amount injected, was found to be 2.2%,
2.6%, and 2.5%, respectively. Clearly, decomposition of
the PITC-derivatized peptide, either before or during
analysis, is not a significant problem.
MRM efficiency was estimated by calculating the
spectrum of PITC-GENFTETDIK obtained at aAD)percentage of the total ion current (TIC) present as the
DIK
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parameters. For example, for PITC-GENFTETDIK (see
Figure 2), the b1 product ion of m/z 193 monitored by
MRM represents 33% of the TIC. For GENFTETDIK, the
product ion of m/z 84 monitored by MRM under con-
ditions optimized for detection of this fragment (see
Figure 4) was 24%, quite similar to that observed for the
b1 ion from the PITC derivative.
Thus, neither chemical instability of PITC derivatives
nor diminished MRM efficiencies of the PITC-peptides
Figure 3. CAD spectrum of GENFTET
Table 1. Optimized MRM response for selected tryptic peptides
Optimized MRM for best y
(or x) ion
Peptide
z  2
precursor
(m/z)
product
ion (m/z)
CE
(V)
Relative
responsea
GENFTETDIK 577.3 706.4(y6) 30 40/3
ESQAYYDGR 544.7 673.3(y5) 28 15/2
VVEQMCTTQYQK 757.8 438.2(y3) 35 1.3/0.2
aResponse relative to the most abundant (100) is given as the mean / SD
bThe ion of m/z 84.1 is the immonium ion of K (or Q) after loss of NH3.can explain the observation that the nanoLC/ESI/MRM
response of PITC-derivatized peptides was significantly
less than that of the underivatized peptides. Presum-
ably, the PITC derivatives have diminished ESI ioniza-
tion efficiency. This has indeed been observed to be true
for MALDI ionization of PITC derivatives [32]. This
problem might be solved by using modified Edman
reagents designed for enhanced ESI ionization effi-
ciency of the product phenylthiohydantoins used in
Edman sequencing [33].
obtained at a collision energy of 30 V.
rPrP
ptimized MRM for best b
(or a) ion
Optimized MRM for best
immonium ion
Product
on (m/z)
CE
(V)
Relative
responsea
product
ion (m/z) CE (V)
Relative
responsea
007.4(b9) 20 2.6/0.3 84.1b 100 100/5
579.2(b5) 22 1.0/0.2 84.1b 100 18/3
171.1(a2) 50 4.8/0.3 84.1b 100 6.3/0.8from
O
i
1(n  8).
E, an
QK).
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underivatized peptides, a PrP quantitation method was
established without use of PITC. Of the three tryptic
peptides that gave the best MRM sensitivity, VVEQM-
CTTQYQK was chosen for quantitation of the prion
protein. GENFTETDIK was excluded because aspara-
gine 197 is modified via N-linked oligosaccharides in
the majority of naturally-occurring PrP molecules. ES-
QAYYDGR was also excluded since the peptide is
Table 2. Optimized MRM response for selected tryptic peptides
Optimized MRM for y(n-1) ion
PITC-peptide
z  2
precursor
(m/z)
Product ion
(m/z)
CE
(V)
Relative
response
GENFTETDIK 644.8 1096.5 (y9) 22 79/8
ESQAYYDGR 612.2 959.4 (y8) 20 32/4
VVEQMCTTQYQK 825.4 1415.6 (y11) 32 16/2
aResponses are given as mean / SD (n  4).
bImmonium ions for the three peptides in descending order are from F,
of 101.072 was observed on the Q-Star from MS/MS of VVEQMCTTQYFigure 4. CAD spectrum of GENFTETDIKabsent in a carboxy-truncated species (about 10% to
15% of total PrP) as observed by others [10]. This leaves
VVEQMCTTQYQK by process of elimination. (PMMH-
FGNDWEDR is another good candidate, but the pres-
ence of two methionines makes possible four isomeric
monosulfoxides (two positional and two diastereo-
meric) and two isomeric disulfoxides (diastereomeric).
For VVEQMCTTQYQK, the a2 product ion of m/z 171
was chosen for MRM detection instead of the somewhat
rP derivatized with PITC
Optimized MRM for b1 ion
Optimized MRM for best
immonium ion
roduction
(m/z)
CE
(V)
Relative
responsea
Product
ion (m/z) CE (V)
Relative
responsea
193.0 (b1) 25 100/10 120.1b 85 16/2
265.1 (b1) 20 42/6 102.1b 56 15/2
235.1 (b1) 32 29/4 101.1b 90 2.2/0.3
d Q, respectively. (Theoreticalm/z for Q is 101.071; for K is 101.107;m/zof rP
a
Pobtained at a collision energy of 100 V.
t sho
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84 is expected from any peptide containing either lysine
or glutamine, whereas the a2 ion should only be seen in
MS/MS of peptides containing amino terminal VV, PK,
or KP, only three of 400 possible dipeptides. A calibra-
tion curve using the optimized 757.8 to 171 transition
(see Figure 5) was obtained with synthetic VVEQMCT-
TQYQK, the amount of which had been quantitated by
amino acid analysis, and using human [Val5]-angioten-
sin II (1 fmol/injection) as internal standard. The results
show a dynamic range of at least three orders of
magnitude. Response is reasonably linear; however the
data more closely fit a second-order polynomial, as
shown. MRM responses for pentuplicate injections of
300 to 2700 amol are shown as an insert in Figure 5. The
results for this range are linear (r2 of 0.996). Error bars in
the insert are displayed as / three times the calcu-
lated standard deviation for visual clarity. The chro-
matographic profile for 0 (solvent only), 300, and 900
amol of VVEQMCTTQYQK is displayed in Figure 6.
Signal to noise (S/N) was calculated using the standard
deviation of the MRM response before elution of the
analyte as an estimate of instrumental noise. For the
pentuplicate injections of 900 amol of VVEQMCT-
TQYQK, a mean S/N of 126 was observed, from which
a limit of detection (LOD) (defined as the amount that
Figure 5. Area of MRM response of VVEQM
standard (1 fmol human [Val5]-angiotensin II) v
bars show the mean  standard deviation (n 
three lowest amounts injected. Data in the insershould give a S/N 3) of 20 amol can be calculated. Forthe pentuplicate injections of 300 amol of VVEQMCT-
TQYQK, a mean S/N of 33 was observed, from which a
LOD of 30 amol can be calculated for detection of the
prion protein. The LOD of 20 to 30 amol achieved by
nanoLC/MRM is nearly four orders of magnitude more
sensitive than the 0.2 pmol sensitivity reported for the
most sensitive antibody-based detection method (vide
supra) [22].
A crude preparation of PrP 27–30 was obtained from
the brains of terminally ill Syrian hamsters inoculated
intracranially with the 263K strain of scrapie. The
sample preparation comprised tissue homogenization,
centrifugation to obtain a sarkosyl-insoluble pellet,
treatment with benzonase and proteinase K, then fur-
ther purification by SDS-PAGE. Three bands are seen
for PrP 27–30 by SDS-PAGE and are known to corre-
spond to molecular species containing 0, 1, or 2 N-
linked glycans per molecule. Our SDS-PAGE separation
clearly resolved the band containing no N-linked gly-
cans from the other two bands that were poorly re-
solved (data not shown). Subsequently, we excised only
two gel regions: one containing PrP with no N-linked
glycans and the other containing PrP with either one or
two N-linked glycans. Excised gel regions were
destained, reduced, alkylated, treated with trypsin, the
QYQK to the MRM response of the internal
s amount of VVEQMCTTQYQK injected. Error
e insert is an expansion of the results from the
w the mean  3 * (standard deviations).CTT
ersu
5). Thresulting peptides were extracted, and the amount of
1078 ONISKO ET AL. J Am Soc Mass Spectrom 2007, 18, 1070–1079VVEQMCTTQYQK was quantitated using the method
described (vide supra).
Recovery experiments were performed to estimate
the overall yield of the chemical, enzymatic, and phys-
ical steps used after isolation of crude PrP 27–30.
Various amounts of rPrP (quantitated by OD at 254 nm)
were subjected to SDS-PAGE, in-gel digestion, and
quantitation of VVEQMCTTQYQK by nanoLC/ESI/
MRM as done for PrP 27–30. The results, shown in
Figure 7, show overall recovery of VVEQMCTTQYQK
from rPrP ranging from 9% to 33%, depending on the
amount of starting rPrP.
The amounts of VVEQMCTTQYQK obtained from
the excised gel pieces from SDS-PAGE of crude PrP
27–30 were corrected using the estimated recoveries
shown in Figure 7, and the results are shown in Table 3.
We estimate 19 ug/g of brain (wet weight) of PrP 27–30
in terminally ill hamsters, composed of 1.2 ug/g of PrP
27–30 containing no N-linked glycans and 17 ug/g of
PrP 27–30 containing N-linked glycans. This result is in
excellent agreement with the estimate by Diringer et al.
[30] of 21 ug/g of PrP 27–30.
Using pure standards, it is straight forward to com-
Figure 6. Elution profile (MRM response) for injection of 0, 300,
and 900 amol of VVEQMCTTQYQK. Data has been smoothed, but
S/N and LOD in the text were calculated using raw data.pare the LOD for our method (30 amol) to that of theCDI (300 amol, calculated from 5 pg protein of MW
16,240) [22]; the mass spectrometric method appears
about ten times more sensitive. Detection of prions in
biological materials is much more difficult, and a com-
parison of the LOD of our method with the CDI starting
with brain can be estimated. To obtain the results for
PrP 27–30 shown in Table 3, crude PrP 27–30 from
0.57 g brain (wet weight) was loaded on each SDS-
PAGE lane, the major band was excised and processed
as described by in-gel digestion to give 150 uL of digest.
After a 10-fold dilution of this digest, 1 uL was injected
onto the nanoLC column, and the MRM response (raw
data not shown) gave a single peak of the correct
retention time with an average S/N for triplicate injec-
tions of 2250. This corresponds to a calculated LOD of
110 amol for PrP 27–30 from brain, about three times
higher than the LOD found with pure standard peptide,
presumably because of the 33% recovery obtained with
this amount of material (see Figure 7). For ng quantities
in brain samples, our % recovery should be about three
times less (see Figure 7), so we estimate the LOD for
detection of ng amounts of PrP 27–30 from brain to be
about 300 amol, which is about 300 times more sensitive
than the reported LOD of 0.1 pmol for the CDI using
rPrP in brain homogenate (2 ng of PrP of MW 16,240)
[22].
In conclusion, we have developed a mass spectro-
metric method for quantitation of the prion protein and
demonstrated its use in detection of PrP 27–30 in the
brains of terminally ill Syrian hamsters. This method is
appropriate for detection of PrPSc, and has better sen-
sitivity than any published antibody-based method.
Figure 7. Recovery of VVEQMCTTQYQK after SDS-PAGE puri-
fication, reduction, alkylation, and tryptic cleavage of recombinant
Syrian hamster PrP comprising amino acids 90–231.
Table 3. Quantitation of PrP 27-30 molecular species in brains
of terminally ill Syrian hamsters
Molecular species Amount ug/g brain)a
PrP 27-30 with no N-linked glycans 1.2/0.2(3)
PrP 27-30 with either 1 or 2 N-
linked glycans
17/ 2(3)
Total 19/ 2(3)aMean / the standard deviation of triplicate analyses.
1079J Am Soc Mass Spectrom 2007, 18, 1070–1079 MASS SPECTROMETRIC DETECTION OF THE PRION PROTEINFuture studies will focus on sample preparation for
attempts to detect PrPSc in blood.
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